Journals / Van Tıp Dergisi / 2018 / Cilt: 25 - Sayı: 2

The Effect of Concomitant Carcinoma In-situ on Oncological Survival in Radical Cycstectomy

Radikal Sistektomi Patolojisinde Eş Zamanlı Karsinoma İn Situ Varlığının Onkolojik Sağkalıma Etkisi

Pages
160–164
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A total of 59 patients with invasive urethelial carcinoma and 14 patients with concomitant CIS were evaluated for 5 years overall and disease free survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We investigated the effect of urethelial carcinoma insitu (CIS) association on cystectomy material on oncologic survival of 73 pat ients who underwent radical cystectomy with diagnosis of invasive urethral carcinoma in our clinic.
📊
Key Findings & Data:Material and Method: Seventy three patients were included in the study who underwent radical cystectomy in our clinic between 2006 and 2011.
💡
Conclusion & Impact:A total of 59 patients with invasive urethelial carcinoma and 14 patients with concomitant CIS were evaluated for 5 years overall and disease free survival.
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: We investigated the effect of urethelial carcinoma insitu (CIS) association on cystectomy material on oncologic survival of 73 pat ients who underwent radical cystectomy with diagnosis of invasive urethral carcinoma in our clinic. Material and Method: Seventy three patients were included in the study who underwent radical cystectomy in our clinic between 2006 and 2011. Urethelial CIS with invasive urethelial carcinoma in cystectomy specimen was detected in 14 patients of 73 cases. A total of 59 patients with invasive urethelial carcinoma and 14 patients with concomitant CIS were evaluated for 5 years overall and disease free survival. Results: The mean age of the 73 patients was 63. The cases were divided into 2 groups; only invasive urethelial carcinomas were detected in 59 patients (80.8%) and 14 patients (19.2%) were diagnosed as urethelial carcinoma in situ with invasive urethelial carcinoma. 38 patients (64%) in the first group and 9 patients (64.4%) in the second group had 5-year disease-free survival. Conclusion: In our study, it was determined that there was no statistical significance on the general and 5-year survival of urethelial CIS detected as a concomitant cystectomy material. However, due to the limited number of patients, we think that prospective studies with a larger number of patients are needed in order to have clearer results.

Özet

Amaç: Kliniğimizde invaziv üretelyal karsinom tanısı ile radikal sistektomi yapılan 73 hastanın transüretral rezeksiyon (TUR) patolojisinde saptanmayıp sistektomi materyalinde eş zamanlı olarak saptanan üretelyal karsinoma insitu (CIS) birlikteliğinin onkolojik sağkalım üzerine etkisini araştırdık. Gereç ve Yöntem: 2006-2011 yılları arasında kliniğimizde invaziv üretelyal karsinom tanısı ile radikal sistektomi yapılan 73 hasta çalışmaya dâhil edildi. 73 hastanın 14’ ünün sistektomi spesmeninde invaziv üretelyal karsinom yanında üretelyal CIS saptandı. Sadece invaziv üretelyal karsinom tanılı 59 hasta ile eş zamanlı CIS tanılı 14 hastanın 5 yıllık genel ve hastalıksız sağkalım sonuçları değerlendildi. Bulgular: Çalışmamıza dâhil edilen 73 hastanın ortalama yaşı 63 olarak hesaplandı. Olgular 2 gruba ayrıldı; birinci grup olarak değerlendirilen 59 hastada (%80,8) sadece invaziv üretelyal karsinom saptanmış olup ikinci grup olarak değerlendirilen 14 hastada (%19,2) ise invazi v üretelyal karsinom patolojisinin yanında eş zamanlı olarak üretelyal karsinoma in situ saptanmıştır. Hastaların 5 yıllık takiplerinde birinci gruptaki 38 olgu (%64), ikinci gruptaki 9 olgunun (%64,4) 5 yıllık hastalıksız sağkalıma sahip olduğu görüldü. Sonuç: Bizim çalışmamızda TUR patolojisinde saptanmayıp sistektomi materyalinde eş zamanlı olarak üretelyal CIS saptanmasının genel ve 5 yıllık sağ kalım üzerine istatistiksel olarak bir etkisinin olmadığı saptandı. Ancak hasta sayısının kısıtlı olması nedeniyle daha net sonuçları ortaya koyabilmek için daha geniş hasta sayısına sahip prospektif çalışmalara ihtiyaç olduğunu düşünmekteyiz.

🔖

Cite This Article

ÖZTÜRK, E., YIKILMAZ, N. T., KESKİN, T. E., HAMİDİ, N., BAŞAR, H. (2018). The Effect of Concomitant Carcinoma In-situ on Oncological Survival in Radical Cycstectomy. Van Tıp Dergisi, Cilt: 25 - Sayı: 2, 160–164. https://ajindex.com/articles/74618

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59(4): 225-249.
  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): 359-386.
  3. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63(2): 234-241.
  4. Steinmaus C, Ferreccio C, Acevedo J, Yuan Y, Liaw J, Durán V, et al. Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure. Cancer Epidemiol Biomarkers Prev 2014; 23(8): 1529- 1538. Skinner DG, Richie JP, Cooper PH, Waisman J, Kaufman JJ. The clinical significance of carcinoma in situ of the bladder and its association with overt carcinoma. J Urol 1974; 112(1): 68-71.
  5. Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol 2002; 168(3): 968-972.
  6. Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000; 164(3,1): 685-689.
  7. Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007; 177(4): 1283-1286.
  8. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59(6): 997-1008. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(3): 466-465.
  9. Habuchi T, Ogawa O, Kakehi Y, Ogura K, Koshiba M, Sugiyama T, et al. Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. J Urol 1992; 148(5): 1595-1599.
  10. Williamson SR, Montironi R, Lopez-Beltran A, MacLennan GT, Davidson DD, Cheng L. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit